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REVIEW
Abstract: Acute renal failure is a common complication in the intensive care unit (ICU).
Over the last 25 years, there have been significant technological advances in the delivery of
renal replacement therapy, particularly as it pertains to the critically ill patient population.
Despite these advances, acute renal failure in critically ill patients continues to carry a poor
prognosis. In this article, we review the current literature about timing and initiation of renal
replacement therapy in the ICU as well as practical considerations regarding the prescription
and delivery of dialysis.
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Introduction
Acute dialysis-dependent renal failure is a common problem in the intensive care
unit (ICU) and, despite significant improvements in the care of critically ill patients,
the mortality from this complication remains over 50%. The development of renal
failure is an independent predictor of mortality in this patient population (Levy et al
1996; Metnitz et al 2002).
Over the last two decades there has been an evolution in the field of hemodialysis
and consequently our approach to the treatment of acute renal failure (ARF). The
use of new devices and techniques has allowed us to achieve better-tolerated and
more efficient renal replacement therapy.
In this article, we review the current literature about renal replacement therapies,
with a focus on continuous therapies and how they may be used in the ICU.
What are the indications for renal replacement
therapy in patients with acute renal failure?
A patient with ARF requires renal replacement therapy (RRT) when he or she has an
acute fall in glomerular filtration rate and has developed, or is at risk of developing
clinically significant solute imbalance/toxicity or volume overload. The precise timing
of RRT initiation is usually a matter of clinical judgment. The classic indications for
dialysis include:
1. diuretic resistant pulmonary edema
2. hyperkalemia (refractory to medical therapy)
3. metabolic acidosis (refractory to medical therapy)
4. uremic complications (pericarditis, encephalopathy, bleeding)
5. dialyzable intoxications (eg, lithium, toxic alcohols, and salicylates).
While many of these indications are typically used in the setting of chronic renal
failure, the consequences of these complications are likely to be more severe in
critically ill patients; therefore, there has been a growing trend to start dialysis prior
to the development of these indications. Delays in the initiation of treatment have
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often been based on a concern that dialysis itself may delay
recovery of renal function. These fears have been largely
dispelled by a recent study by Schiffl et al (2002), which
compared outcomes in patients with ARF treated with daily
vs alternate day dialysis for patients with ARF. Daily dialysis
was not associated with a delay in renal recovery or an
adverse effect on patient outcome.
What types of renal replacement
therapy are available for use in the
intensive care unit?
The available modalities of renal replacement therapy
include:
• peritoneal dialysis (PD)
• intermittent hemodialysis (IHD)
• continuous renal replacement therapies (CRRT).
Peritoneal dialysis
Peritoneal dialysis uses the peritoneum as a natural semi-
permeable membrane for diffusive removal of solutes. It is
a very effective treatment modality in patients with chronic
renal failure, and patient outcomes are at least equivalent to
those treated with hemodialysis (Held et al 1994; Murphy
et al 2000). Peritoneal dialysis is also valuable in pediatric
critical care where vascular access is challenging and
peritoneal surface area is relatively larger than in adults
(Williams et al 2002).
In adult patients, acute peritoneal dialysis is not widely
used. The use of peritoneal dialysis is limited by both
logistical and practical considerations. Acute peritoneal
dialysis requires surgical insertion of a peritoneal dialysis
catheter, requiring the additional involvement of a surgical
team. Acute PD is frequently complicated by catheter
leakage and malfunction. In addition, the use of PD is limited
by low solute clearance in hypercatabolic patients, potential
pulmonary restriction due to expansion of the peritoneal
cavity, and its contraindication in postoperative patients who
require abdominal surgery or surgical drains (Phu et al
2002). A study comparing PD with CRRT in critically ill
septic patients with ARF showed more rapid correction of
acidosis, solute clearance, and significantly improved
survival with CRRT (Phu 2002).
Intermittent hemodialysis
Hemodialysis is a process of solute clearance based on
diffusion across the membrane driven by a concentration
gradient between the blood and dialysate. The total amount
of solute transported per unit of time (clearance), depends
on the molecular weight of the molecule, membrane
characteristics (dialysance), dialysate flow, and blood flow.
In general, intermittent dialysis is prescribed for 3–6 h per
treatment. Chronic hemodialysis patients are treated three
times per week, the adequate dose for IHD in patients with
ARF has not yet been determined.
Slow efficiency daily dialysis (SLEDD) or EDD
(extended daily dialysis) is a variant of IHD where the
duration of dialysis is extended to between 8 and 12 h, the
blood flow is lowered, fluid removal is more gradual, and
solute clearance slower. SLEDD is associated with less
hemodynamic instability than IHD and provides excellent
solute control (Kihara et al 1994). This modality may have
several advantages over continuous renal replacement
therapies with respect to cost and improved patient mobility,
however the two therapies have never been compared
directly in a clinical trial.
Continuous renal replacement therapy (CRRT) has
become increasingly popular for the management of ARF
in the critically ill, and is now used to the exclusion of IHD
in Australia (Mehta and Letteri 1999; Silvester et al 2001;
Mendelssohn and Hyman 2002).
Continuous renal replacement therapies
(CRRT)
CRRT is any renal replacement therapy that is intended to
be applied for 24 h per day in an ICU. The term CRRT
describes a variety of blood purification techniques, which
may differ significantly according to the mechanism of
solute transport, the type of membrane, the presence or
absence of dialysate solution, and the type of vascular access.
CRRT provides slower solute clearance per unit time as
compared with intermittent therapies but over 24 h may even
exceed clearances with IHD.
Solute removal with CRRT is achieved either by
convection (hemofiltration), diffusion (hemodialysis), or a
combination of both these methods (hemodiafiltration).
Hemodialysis most efficiently removes small molecular
weight substances such as urea, creatinine, and potassium.
Middle and larger molecular weight substances are more
efficiently removed using hemofiltration as compared with
dialysis. During hemofiltration, hydrostatic pressure causes
the filtration of plasma across a semi-permeable membrane.
Solutes are dragged across the membrane along with the
plasma resulting in convective transport of solutes in theTherapeutics and Clinical Risk Management 2005:1(2) 143
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same direction as water. This process requires the use of
replacement fluid to prevent iatrogenic acidosis and
electrolyte depletion as well as excessive fluid removal. The
solutes in the removed filtrate are in the same concentration
as those in the plasma, and solute concentration in the
remaining plasma is diluted with substitution fluid.
Combining diffusive and convective clearance with
hemodiafiltration allows improved clearance of both small
and large molecular weight substances. Using this method,
blood urea nitrogen (BUN) clearances in the range of
23–30 mL/min can be achieved, even in hypotensive patients
(McDonald and Mehta 1990).
The choice of modality is dependent on several factors
including availability, cost, physician expertise, hemo-
dynamic stability, and the primary purpose of the procedure
(fluid removal vs solute clearance). There is currently only
limited information comparing diffusive with convective
blood purification techniques; results with CRRT techniques
should be compared with those obtainable with IHD, which
remains the gold standard therapy.
The most commonly applied modalities are continuous
venovenous hemofiltration (CVVH), continuous veno-
venous hemodialysis (CVVHD), and continuous
venovenous hemodiafiltration (CVVHDF). Arteriovenous
(AV) modes of CRRT have been used in the past, whereby
dialysis access was obtained through the femoral artery and
the femoral vein. This type of CRRT used the patient’s own
cardiac output to drive blood through the dialysis circuit.
AV forms of CRRT have fallen out of favor in recent years
due to the high access complication rate and the development
of external circuit pumps. See Table 1 for a comparison of
intermittent vs continuous dialysis therapies.
When should renal replacement
therapies be started?
There is no commonly accepted definition for the timing of
initiating renal replacement therapy in ARF. It has been
suggested that patient outcome can be improved by early
or more intensive dialysis to keep the BUN under
80–100 mg/dL (29–36 mmol/L). Recent nonrandomized
studies have not been able to document significant benefit
of prophylactic dialysis (Gillum et al 1986; Conger 1995).
It is interesting to note that the average urea concentration
at initiation of CRRT in a recent Italian study of dialysis
dosage was 17 mmol/L (Ronco 2000), however there is
considerable variation in practice. A recent American
survey of ICU dialysis practices found that the mean BUN
and creatinine values at the initiation of dialysis were
34 mmol/L and 398 µmol/L, respectively (Lewis 1997).
However, because the BUN may reflect many factors other
than the timing of initiation, no absolute value for BUN or
creatinine should be used to determine when to initiate
dialysis.
Only one randomized controlled trial has looked at the
effect of timing of initiation of renal replacement therapy
on outcome. Bouman et al randomized 106 critically ill
patients with ARF to early vs late initiation of dialysis. Early
initiation was started within 12 h of patients meeting the
following criteria; low urine output (< 30 cc/h) × 6 h
refractory to optimization of hemodynamics and diuretics,
and creatinine clearance of < 20 mL/min (Bouman et al
2002). The late initiation group was started on dialysis when
the classic indications for dialysis were met (volume
overload, hyperkalemia, urea greater than 40 mmol/L). There
was no significant difference between the groups in terms
of ICU or hospital mortality, and no difference with respect
to recovery of renal function. The results of this study must
be interpreted with some caution however, as the study was
underpowered to detect a clinically significant difference
and the mortality rate in all treatment groups was very low.
The Acute Dialysis Quality Initiative (ADQI) consensus
statement on dialysis treatment (Kellum, Mehta, et al 2002),
makes no recommendations on the timing of initiation of
renal replacement therapy beyond those defined by the
conventional criteria that apply to chronic renal failure.
How is dialysis dose measured in
acute renal failure?
In the end-stage renal failure population, dialysis dose has
been quantified using a technique called urea kinetic
Table 1 A comparison of intermittent vs continuous dialysis
therapies
CRRT IHD
Time 24 hours 4–6 hours
Pump speed 100–180 mL/min 200–500 mL/min
Dialysis membrane 0.9 m
2 1.1–2.1 m
2
High flux +/– High flux
Dialysis flow rate 0–2 L/h 500–750 mL/min
Replacement fluid 1–3 L/h None
Fluid removal +100 mL/h to 500–1000 mL/h
 –500 mL/h
Abbreviations: CRRT, continuous renal replacement therapies; IHD, intermittent
hemodialysis.Therapeutics and Clinical Risk Management 2005:1(2) 144
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modeling (UKM). Absolute concentrations of urea and
creatinine are difficult to interpret; however, clearance of
these marker substances appears to be the best measurement
of therapy dose as it considers generation rates as well as
plasma clearance. While quantification of dialysis dose using
UKM is intuitive with intermittent therapies, methods for
measuring clearance in CRRT are variable, hampered in part
by a lack of understanding of what parameters should be
used to compute dialysis dosage. The total solute clearance
in CRRT techniques is the sum of the convective and
diffusive clearances (Siegler and Teehan 1987), which is,
in practical terms, the hourly volume of effluent fluid
(ultrafiltrate and dialysate). Since the molecular weight cut
off for the membranes is > 20 000 Daltons, most low and
middle molecular weight substances have sieving
coefficients (SC) of 1. Convective clearance is therefore
directly proportional to the amount of filtrate produced.
Small molecules are less dependent on convective clearance
and are more effectively transferred by diffusion. Slow
dialysate flow rates (1–2 L/h) allow for complete saturation
of the dialysate fluid with solutes. CRRT clearance is
commonly expressed as the L/kg/h of effluent.
At the present time, a UKM-based calculation of plasma
solute clearance is the most common method measurement
of dialysis dosage with both intermittent and continuous
forms of dialysis, although it is not entirely clear that the
calculated clearance values can be directly compared
(Siegler and Teehan 1987). This calculation is called Kt/V,
where K is clearance, t is duration of dialysis, and V is the
volume of distribution of urea. The limitation of this method
rests in the observation that critically ill patients with ARF
are frequently catabolic and have highly variable fluid
volumes; both conditions violate several of the assumptions
implicit in urea kinetic modeling. Quantification of solute
clearance using dialysate concentrations of clearance
markers (calculation of a solute removal index [SRI]) avoids
some of the limitations of blood-based clearance
calculations. There is no consensus as to which method
should be used in all clinical situations.
What is the appropriate dose of
dialysis?
The notion of dialysis dose quantification in ARF has been
controversial, due in part, to the lack of convincing evidence
that azotemia control affects outcome in patients with either
acute or chronic renal failure. At the present time there is
no consensus as to what the minimal dialysis dose should
be in patients with ARF. Extrapolating data from the end-
stage renal disease (ESRD) population (Gotch and Sargent
1985), it seems reasonable to suggest a minimum Kt/V of
1.2 should be delivered at least three times a week in patients
with ARF. However, several recent studies support the belief
that more intensive dialysis may be beneficial in this patient
group. A randomized dose-intensity study of CVVH in 425
critically ill patients demonstrated a significant decrease
in patient mortality when ultrafiltration rates of 35 mL/kg/h
(approximately 3 L/h in a 70 kg male) were used as compared
with 20 mL/kg/h (Ronco et al 2000). A randomized trial of
intermittent hemodialysis comparing daily with alternate day
dialysis showed a reduction in mortality from 46% to 28%
(p < 0.05) (Schiffl et al 2002). Unfortunately the delivered
dialysis dose in the alternative day group as measured by
weekly Kt/V was less than 3.6, the minimally acceptable
dose in chronic dialysis patients, thus the issue of minimal
adequate dose remains unresolved.
Practical issues regarding renal
replacement therapy in the ICU
Vascular access
Vascular access for acute intermittent hemodialysis must
be obtained using double lumen dialysis catheters. These
may be inserted in the internal jugular, subclavian, or femoral
veins. If possible, subclavian vein cannulation should be
avoided because of a high incidence of subsequent venous
stenosis, which may significantly complicate venous access
if chronic hemodialysis is required (Stalter et al 1986;
Cimochowski et al 1990; Bambauer et al 1994). Blood
recirculation from the venous to the arterial port can reduce
the effectiveness of dialytic therapies, particularly during
IHD. Use of a short 13.5-cm catheter in the femoral vein
may result in up to 23% blood flow recirculation and can
be avoided by using longer catheters (19–25 cms) when
using the femoral vein for vascular access (Kelber et al
1993).
Access to blood supply for the extra corporeal circuit
varies with CRRT techniques. Arteriovenous techniques,
which have largely fallen out of favor, generally require
cannulation of the femoral artery and the femoral vein. The
variable blood flow rates lead to a higher risk of thrombosis.
In general, large bore, small length catheters are preferable
for AV procedures to permit a high blood flow rate. In
pumped (venovenous) systems double lumen venous
catheters are commonly used; the size should be selected
based on the site of insertion to optimize flow.Therapeutics and Clinical Risk Management 2005:1(2) 145
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Membranes
Membrane characteristics that should be considered when
selecting membranes for hemodialysis or CRRT include
solute removal, water permeability, and biocompatibility.
Dialyzer efficiency (KoA) is extremely important in IHD
where therapy is administered over a relatively short period
of time with high blood and dialysate flow rates. Generally
speaking, the efficiency of small solute clearance in CRRT
is largely determined by dialysate/ultrafiltration flow rate;
therefore, solute removal characteristics are not an important
factor in choosing a dialysis membrane. High flux
membranes, which are designed to provide high water
permeability, are generally recommended for hemofiltration
procedures. Finally, although there is no conclusive evidence
that membrane biocompatibility affects patient outcome,
there is general consensus (Kellum, Mehta, et al 2002) that
the use of synthetic membranes is preferable over cellulose-
based membranes for the treatment of patients with ARF.
Replacement/Dialysate solutions
Dialysate for intermittent hemodialysis is generally
produced on-line by the dialysis machine from a
combination of treated water and various electrolytes. There
are stringent standards for water quality in the hemodialysis
unit set out by the American Association of Medical
Instrumentation (AAMI). Water purification is generally
achieved by treatment with reverse osmosis, deionization,
and the use of charcoal filters. Dialysate water is not required
to be sterile as there is no contact between blood and
dialysate.
All CRRT techniques other than slow continuous
ultrafiltration (SCUF) require the use of sterile dialysate/
replacement fluids to compensate for the ultrafiltrate
removed. Although dialysate does not come into direct
contact with blood given the low blood-side pressures, back-
filtration (dialysate to blood) may readily occur, particularly
with high permeability membranes (Golper 1989).
Optimal dialysate/replacement solution approximates
normal plasma water composition, replacing electrolytes and
minerals in physiologic concentrations without replacing
the metabolic solutes, which accumulate in renal failure.
The composition of these solutions can be varied extensively
to achieve specific metabolic goals (eg, bicarbonate-based
solutions can be used to correct acidemia and the electrolyte
content can be altered to correct electrolyte imbalance)
(Macias and Clark 1996; Palevsky 1996). A limitation of
using sterile solution for CRRT is that they are acetate or
lactate based and the capacity to convert these buffers to
bicarbonate may be limited in patients with multiple organ
failure (Levraut 1997). More recently, bicarbonate-based
solutions, which are better tolerated than lactate- or acetate-
based solutions, have become commercially available
(Zimmerman et al 1999).
When citrate anticoagulation is used in CRRT,
modifications are necessary in both the replacement fluid
and dialysate; often necessitating the use of customized,
locally prepared solutions as commercially available
solutions are not widely available. Citrate is metabolized to
bicarbonate by the liver; therefore buffer is not generally
required in the dialysate. Similarly, dialysate used in citrate
regional anticoagulation is generally hyponatremic to
prevent hypernatremia, and it is recommended that fluids
are calcium free. Few commercially available calcium free,
bicarbonate-based CRRT fluids have been available until
recently. This has led many centers to produce such fluids
in-house using pharmacy total parenteral nutritional (TPN)
manufacturing facilities. Manufacturing error in the
pharmacy led to pharmacy technicians using concentrated
potassium chloride instead of concentrated sodium chloride
in the production of CRRT fluid in Calgary, Canada, in the
last year and resulted in the deaths of 2 critically ill patients.
Both electrolyte solutions had been provided in almost
identically labeled containers. A commercially available
solution is supplied as a concentrate, which is added to 3-L
bags of sterile water. Failure by critical care bedside nurses
to add the concentrate to the sterile water has resulted in the
deaths of 2 patients in Toronto, Canada, from massive
hemolysis. These tragedies underscore the importance of
using commercially prepared solutions; if addition of
concentrate to sterile water is required, this should be done
in a pharmacy setting.
Anticoagulation
Anticoagulation is an essential component of all blood-based
renal replacement therapies, including CRRT. The passage
of blood through an extracorporeal circuit causes platelet
activation and induces a variety of inflammatory and
prothrombotic mediators, resulting in fibrin deposition on
filter membranes. This not only affects filter longevity, but
may also decrease dialyzer efficacy in terms of water and
solute removal. If anticoagulation is insufficient, filtration
performance deteriorates and the filter may clot, contributing
to blood loss and additional costs related to filter
replacement. Excessive anticoagulation may result inTherapeutics and Clinical Risk Management 2005:1(2) 146
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bleeding complications, reported to occur in 5%–26% of
treatments (Webb et al 1995).
Unfractionated heparin is the mainstay of anti-
coagulation for IHD and CRRT (Favre et al 1996). Heparin
is generally administered as a bolus, followed by a
continuous infusion into the arterial limb of the dialysis
circuit, to maintain a partial thromboplastin time (PTT) of
1.5–2 × normal. Low molecular weight heparin is excreted
renally and should not be used without careful monitoring
of factor Xa levels in patients with ARF (Schrader et al
1990).
Systemic anticoagulation is relatively contraindicated in
patients at high risk of bleeding, although the heparin dose
can be modified in these circumstances. Its use, however, is
associated with a high incidence of bleeding and in some
instances heparin-induced thrombocytopenia (Mehta et al
1992). Because of the shorter duration and high blood flow
used, it is often possible to perform IHD without
anticoagulation, particularly when the patient is coagulo-
pathic. In heparin-free dialysis, blood flows are kept between
250–500 mL/min and saline flushes are administered every
15–30 min into the arterial limb of the dialysis circuit to
minimize hemoconcentration and to wash fibrin strands from
the kidney into the bubble trap. The volume of saline
administered with such frequent flushing must be removed
during the dialysis to prevent hypervolemia. This technique
is associated with only a 2% clotting rate (Schwab et al
1987).
In newly postoperative patients and others with a
contraindication to systemic anticoagulation, regional
anticoagulation of the circuit is preferred. Regional
heparinization, with pre-filter administration of heparin, and
a post-filter protamine infusion has been used (Swartz and
Port 1979; Abramson and Niles 1999), but regional citrate
anticoagulation has become increasingly popular. Citrate
anticoagulation may be used with both continuous and
intermittent therapies. Regional citrate anticoagulation is
achieved using a continuous citrate infusion through the
arterial limb of the circuit, which chelates free calcium and
inhibits the coagulation cascade. The citrate-calcium
complex is removed by a combination of dialysis clearance
against calcium-free dialysate and endogenous processes.
In patients with normal liver function, levels of citrate and
ionized calcium return to normal values within 30 min of
discontinuing a citrate infusion (Mehta et al 1990). Plasma
calcium levels are restored with the use of a continuous
calcium infusion at the site of blood return to the patient.
The infusion rate of citrate is adjusted to keep the activated
clotting time (ACT) above 160 s. Regional citrate
anticoagulation requires the use of a specialized dialysis
solution and frequent monitoring of ionized calcium
(Kutsogiannis et al 2000). Potential complications arising
from this technique include metabolic alkalosis, hypo-
natremia, hypocalcaemia, and citrate toxicity in patients with
liver dysfunction. If properly monitored, the complication
rate associated with this technique is quite low (Flanigan et
al 1987). When used with CRRT techniques, filter longevity
in excess of 96 h is fairly common with citrate
anticoagulation, while 36–48 h patency is usually the norm
with heparin (Bellomo 1993).
Low molecular weight heparin (Hory et al 1985;
Wynckel et al 1991), prostacyclin analogues (Davenport et
al 1994), and other anticoagulants such as danaparoid
(Chong and Magnani 1992) and high molecular weight
dextran (Palevsky et al 1995) have been used with both
continuous and intermittent renal replacement therapies
(Campbell 1999). See Table 2 for a comparison of
anticoagulation strategies.
At the current time none of these methods is ideal, and
selection is usually influenced by patient factors. Technical
factors and experience with anticoagulants are important
determinants of the success of any anticoagulation regimen.
Does CRRT confer an advantage
over IHD in the management of
acute renal failure?
CRRT has several theoretical advantages over intermittent
blood purification techniques, including better
hemodynamic tolerability, more efficient solute clearance,
better control of intravascular volume, and better clearance
of middle and large molecular weight substances.
Hypotension is one of the most common complications
associated with intermittent hemodialysis, occurring in
approximately 20%–30% of all treatments. Some of the
causes are dialysis specific, such as excessive or rapid
volume removal, changes in plasma osmolality, and
autonomic dysfunction. In critically ill patients who may
be hemodynamically unstable, it would be desirable to
minimize this complication, as it may lead to further organ
ischemia and injury. Several prospective and retrospective
studies have demonstrated better hemodynamic stability
associated with CRRT (Paganini et al 1984; Davenport et al
1993); however, this observation has not been validated in
a randomized controlled trial.Therapeutics and Clinical Risk Management 2005:1(2) 147
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Another advantage of CRRT is the improved efficiency
of solute removal. Although the clearance rate of small
solutes is slower per unit time with CRRT (17 mL/min vs
more than 160 mL/min with conventional hemodialysis),
CRRT is continuously administered; therefore, urea
clearance is more efficient after 48 h than with alternate day
intermittent hemodialysis. Clark et al (1997) developed a
computer model based on 20 critically ill patients to compare
solute clearance in intermittent and continuous renal
replacement therapies, and found that for a 50 kg male, an
average of 4.4 dialysis sessions/week would be required to
achieve equivalent uremic control. In patients with a weight
greater than 90 kg, equivalent uremic control could not be
achieved with intermittent therapies even if daily dialysis
was prescribed.
Fluid management is often a difficult issue in ICU, where
nutritional requirements (TPN) and the use of IV
medications necessitate the administration of large amounts
of fluid to critically ill patients. The inability to severely
fluid restrict fluid intake in ICU patients results in excessive
volume overload, which may compromise tissue perfusion
and has been associated with adverse outcomes (Mehta et
al 2002). Attempts to restrict fluid in this setting may
additionally compromise adequate nutrition (Campbell
1999). The capacity to adjust fluid balance on an hourly
basis, even in hemodynamically unstable patients, is largely
responsible for the growing popularity of CRRT.
CRRT may also have an immunomodulatory effect. The
rationale for the use of CRRT for the treatment of sepsis
arises from the observed association between sepsis severity
Table 2 Anticoagulation modalities for continuous renal replacement
Maintenance 
Method Filter prime Initial dose dose Monitoring Advantages Disadvantages
Saline solution 2 L saline 150–250 mL 100–250 mL/h Visual check No anticoagulant used Poor filter patency
pre-filter pre-filter
Heparin 2 L saline 5–10 U/kg 3–12 /kg/h ACT 200–250; Standard method; Bleeding risk;
2500–10000 U PTT 1.5–2.0 × normal easy to use; thrombocytopenia
inexpensive
LMW heparin 2 L saline 40 mg 10–40 mg/6 h Factor Xa levels; Decreased risk of Special monitoring; not
maintained between bleeding available everywhere;
0.1–0.41 U/mL expensive
Regional 2500 U/2 L 5–10 U/kg 3–12 U/kg/h; PTT: post-filter Reduced bleeding risk Complex; risk of
heparin saline + protamine ACT 200–250 thrombocytopenia;
post-filter protamine effects;
hypotension
Regional 2 L saline 4% trisodium 100–180 mL/h ACT: 200–250 maintain No bleeding; no Complex; needs Ca
citrate citrate 3–7% of BFR, ionized calcium thrombocytopenia; monitoring; alkalosis
150–180 mL/h Ca replaced by 0.96–1.2 mmol/L improved filter efficacy,
central line longevity
Prostacyclin 2 L saline 4–8 ng/kg/min 4–8 ng/kg/min Usually no monitoring Alternative to heparin May need low-dose
+ heparin  if heparin not and citrate. Usually in heparin addition;
required liver failure hypotension
Hirudin 2 L saline 625 µg/kg/h 6–25 µg/kg/h PTT,  Ecarin Alternative to heparin. Bleeding risk; no reversal
(Monitor clotting time Usually used if HITT agent
carefully in
renal failure)
Danaparoid 2 L saline 2500 U bolus 400 IU/h PTT antifactor Xa Alternative to heparin.  Bleeding; no reversal agent
Usually used if HITT
Argatroban 2 L saline – 2 µg/kg/min PTT Alternative to heparin. Bleeding risk; no reversal
(reduce in Usually used if HITT agent
hepatic
dysfunction)
Nafomostat 2 L saline – 0.1 mg/kg/h ACT Alternative to heparin Bleeding
mesilate
Source: Mehta RL. 1992. New developments in continuous arterio-venous hemofiltration/dialysis. In Andreucci VE, Fine L (eds). International Yearbook of Nephrology,
1992. Heidelberg: Springer. Copyright © Springer Verlag. Reproduced with permission from Springer Verlag. NOTE: Dashes mean no loading dose. Abbreviations: ACT,
activated clotting time; BFR, blood flow rate; HITT, heparin induced thrombocytopenia; LMW, low molecular weight; PTT, partial thromboblastin time.Therapeutics and Clinical Risk Management 2005:1(2) 148
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mortality rate and serum concentrations of various cytokines
including TNF, IL1, IL6, and IL8. Most of these middle
molecular weight molecules are water-soluble and are
theoretically removable by hemofiltration-based plasma
water purification. At the present time the immuno-
modulatory effects of CRRT remain theoretical and have
not been shown to affect outcome in human studies (Honore
2000; Cole 2002).
Despite its apparent advantages over intermittent
therapies, superiority of CRRT with respect to mortality or
recovery of renal function has not been demonstrated. In
the largest randomized controlled trial to date (n = 166),
intermittent hemodialysis was associated with significantly
lower in-hospital (48% vs 65%) and ICU mortality (42%
vs 60%). However, patients with hypotension were excluded
from participating in the study, and there was a significant
difference in severity scores between the treatment arms
despite randomization (Mehta et al 1996). Two recently
published meta-analyses compared intermittent with
continuous renal replacement therapies in unselected
critically ill patients (Kellum, Angus, et al 2002; Tonelli et
al 2002). Both concluded that there was no difference in
terms of renal recovery. However, while Kellum concluded
there was improved survival with CRRT, Tonelli found no
survival benefit with either modality. Moreover, the sample
size required to show a 20% mortality difference between
IHD and CRRT would be in excess of 1200 patients (Tonelli
et al 2002).
There are also significant cost implications associated
with modality choice for treatment of ARF in the ICU
setting. A study comparing CRRT to alternate day IHD
showed CRRT to be significantly more expensive, primarily
because of the cost of CRRT fluid (Mann et al 2003). Cost
differences also depend on whether these procedures are
performed by critical care nurses or by renal unit nurses
and whether inter-unit charges are applied.
Further studies are needed to define the subset of patients
with ARF who benefit from this therapy.
Are there non-renal indications for
CRRT?
While the use of CRRT in critically ill patients with ARF is
widely accepted, CRRT has also been used for some non-
renal indications, most notably for the treatment of septic
shock. Studies of high volume hemofiltration (HVHF) in
canine (Silvester 1997) and porcine models (Grootendorst
et al 1992) of sepsis showed significant improvement in
CO, MAP, SV, and hepatic arterial flow. A small study found
similar benefit in severe human septic shock (Honore 2000);
however, a subsequent randomized clinical trial failed to
confirm these findings (Bouman 2002).
There are case reports and case series of CRRT use in a
variety of other conditions including liver support, elevated
ICP, intoxication, cardiac failure, ARDS, rhabdomyolysis,
tumor lysis syndrome, post-cardiac surgery, but few if any
prospective studies for many of these conditions (Schetz
1999). At present there are no established nonrenal
indications for CRRT.
Looking to the future
As experience with these techniques grows, innovations in
technology will likely keep pace. Over the last three years,
most of the major manufacturers of dialysis equipment have
developed new pumps dedicated for the use of these
therapies. Most of these devices (Hospal/Gambro/Cobe-
PRISMA, Fresenius-Acumen, Baxter-Accura, Edwards-
Aquarius) offer automated fluid balancing, and sophisticated
controls that are similar to those in regular dialysis machines.
Membrane technology is also evolving and anti-
thrombogenic membranes are on the horizon (Yang 1991).
Finally, the application of these therapies is likely to expand
to other arenas including the treatment of sepsis, congestive
heart failure, multiorgan failure, as a form of liver support,
and in cardiopulmonary bypass for cytokine manipulation.
It remains to be seen how these therapies will change our
current management of these patient groups.
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